Literature DB >> 24121974

OxLDL-induced IL-1 beta secretion promoting foam cells formation was mainly via CD36 mediated ROS production leading to NLRP3 inflammasome activation.

Weiwei Liu, Yanlin Yin, Zihui Zhou, Min He, Yalei Dai.   

Abstract

OBJECTIVE: IL-1β is a master switch of inflammation and plays an important role in the pathogenesis of vascular disease. During early atherosclerosis development, it is not clearly understood how oxidized low density lipoprotein (oxLDL)induced signaling pathways control NLRP3 inflammasome activation and produce IL-1β and promote foam cells formation.
METHODS: The study used THP-1 macrophage as cell model. Western blot quantified the oxLDL-induced NLRP3 inflammasome related proteins. The FACS detected the expression of SR-A and CD36 receptors on the cells, and caspase-1 activation in the cells. The DCFH-DA assayed the reactive oxygen species (ROS). Oil red O staining techniques examined the intracellular lipid droplet.
RESULTS: The OxLDL remarkably increased not only IL-1β mRNA transcription and pro-IL-1β protein synthesis but also IL-1β secretion in human macrophages. The activation of the NLRP3 inflammasome depended on oxLDL-induced generation of ROS, potassium efflux and cathepsin B activity. The OxLDL-induced ROS production that mediates IL-1β maturation mainly depended on the scavenger receptor of CD36 but not SR-A. The secreted IL-1β served as an autocrine function for promoting macrophage foam cells formation.
CONCLUSIONS: These findings suggest that oxLDL-induced NLRP3 inflammasome activation mainly depends on CD36 involved in the progression of atherosclerosis by promoting oxLDL-mediated inflammation and foam cell formation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24121974     DOI: 10.1007/s00011-013-0667-3

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  38 in total

Review 1.  The immune response in atherosclerosis: a double-edged sword.

Authors:  Göran K Hansson; Peter Libby
Journal:  Nat Rev Immunol       Date:  2006-06-16       Impact factor: 53.106

2.  ROS and NF-kappaB but not LXR mediate IL-1beta signaling for the downregulation of ATP-binding cassette transporter A1.

Authors:  Min Chen; Wenjing Li; Nanping Wang; Yi Zhu; Xian Wang
Journal:  Am J Physiol Cell Physiol       Date:  2006-11-29       Impact factor: 4.249

3.  Gout-associated uric acid crystals activate the NALP3 inflammasome.

Authors:  Fabio Martinon; Virginie Pétrilli; Annick Mayor; Aubry Tardivel; Jürg Tschopp
Journal:  Nature       Date:  2006-01-11       Impact factor: 49.962

4.  Endotoxin down-regulates ABCG5 and ABCG8 in mouse liver and ABCA1 and ABCG1 in J774 murine macrophages: differential role of LXR.

Authors:  Weerapan Khovidhunkit; Arthur H Moser; Judy K Shigenaga; Carl Grunfeld; Kenneth R Feingold
Journal:  J Lipid Res       Date:  2003-06-01       Impact factor: 5.922

5.  Absence of CD36 protects against atherosclerosis in ApoE knock-out mice with no additional protection provided by absence of scavenger receptor A I/II.

Authors:  Sai Kuchibhotla; Difernando Vanegas; David J Kennedy; Ella Guy; George Nimako; Richard E Morton; Maria Febbraio
Journal:  Cardiovasc Res       Date:  2007-12-07       Impact factor: 10.787

6.  Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica.

Authors:  Catherine Dostert; Virginie Pétrilli; Robin Van Bruggen; Chad Steele; Brooke T Mossman; Jürg Tschopp
Journal:  Science       Date:  2008-04-10       Impact factor: 47.728

7.  Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization.

Authors:  Veit Hornung; Franz Bauernfeind; Annett Halle; Eivind O Samstad; Hajime Kono; Kenneth L Rock; Katherine A Fitzgerald; Eicke Latz
Journal:  Nat Immunol       Date:  2008-07-11       Impact factor: 25.606

8.  CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer.

Authors:  Cameron R Stewart; Lynda M Stuart; Kim Wilkinson; Janine M van Gils; Jiusheng Deng; Annett Halle; Katey J Rayner; Laurent Boyer; Ruiqin Zhong; William A Frazier; Adam Lacy-Hulbert; Joseph El Khoury; Douglas T Golenbock; Kathryn J Moore
Journal:  Nat Immunol       Date:  2009-12-27       Impact factor: 25.606

9.  Interleukin-1beta and tumour necrosis factor-alpha impede neutral lipid turnover in macrophage-derived foam cells.

Authors:  Jenny Persson; Jan Nilsson; Marie W Lindholm
Journal:  BMC Immunol       Date:  2008-11-25       Impact factor: 3.615

Review 10.  Cytokines and atherosclerosis: a comprehensive review of studies in mice.

Authors:  Robert Kleemann; Susanne Zadelaar; Teake Kooistra
Journal:  Cardiovasc Res       Date:  2008-05-16       Impact factor: 10.787

View more
  59 in total

1.  CD13 deficiency leads to increased oxidative stress and larger atherosclerotic lesions.

Authors:  Charan V Devarakonda; Flavia E Pereira; Jonathan D Smith; Linda H Shapiro; Mallika Ghosh
Journal:  Atherosclerosis       Date:  2019-06-13       Impact factor: 5.162

2.  Methionine oxidized apolipoprotein A-I at the crossroads of HDL biogenesis and amyloid formation.

Authors:  Andrzej Witkowski; Gary K L Chan; Jennifer C Boatz; Nancy J Li; Ayuka P Inoue; Jaclyn C Wong; Patrick C A van der Wel; Giorgio Cavigiolio
Journal:  FASEB J       Date:  2018-01-17       Impact factor: 5.191

Review 3.  CD36 in chronic kidney disease: novel insights and therapeutic opportunities.

Authors:  Xiaochun Yang; Daryl M Okamura; Xifeng Lu; Yaxi Chen; John Moorhead; Zac Varghese; Xiong Z Ruan
Journal:  Nat Rev Nephrol       Date:  2017-09-18       Impact factor: 28.314

4.  Highlighting Residual Atherosclerotic Cardiovascular Disease Risk.

Authors:  Yunosuke Matsuura; Jenny E Kanter; Karin E Bornfeldt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-01       Impact factor: 8.311

5.  The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study.

Authors:  Arwa Younis; Dana Eskenazi; Ronen Goldkorn; Jonathan Leor; Nili Naftali-Shani; Enrique Z Fisman; Alexander Tenenbaum; Ilan Goldenberg; Robert Klempfner
Journal:  Cardiovasc Diabetol       Date:  2017-05-22       Impact factor: 9.951

6.  Regulation of oxidized LDL-induced inflammatory process through NLRP3 inflammasome activation by the deubiquitinating enzyme BRCC36.

Authors:  Mohit Singh; Bhawna Kumari; Umesh C S Yadav
Journal:  Inflamm Res       Date:  2019-09-04       Impact factor: 4.575

7.  Oxidized Low-Density Lipoprotein Immune Complex Priming of the Nlrp3 Inflammasome Involves TLR and FcγR Cooperation and Is Dependent on CARD9.

Authors:  Jillian P Rhoads; John R Lukens; Ashley J Wilhelm; Jared L Moore; Yanice Mendez-Fernandez; Thirumala-Devi Kanneganti; Amy S Major
Journal:  J Immunol       Date:  2017-01-27       Impact factor: 5.422

8.  The IRAK-ERK-p67phox-Nox-2 axis mediates TLR4, 2-induced ROS production for IL-1β transcription and processing in monocytes.

Authors:  Ankita Singh; Vishal Singh; Rajiv L Tiwari; Tulika Chandra; Ashutosh Kumar; Madhu Dikshit; Manoj K Barthwal
Journal:  Cell Mol Immunol       Date:  2015-08-31       Impact factor: 11.530

Review 9.  Protein Oxidation in Aging: Does It Play a Role in Aging Progression?

Authors:  Sandra Reeg; Tilman Grune
Journal:  Antioxid Redox Signal       Date:  2014-10-09       Impact factor: 8.401

10.  Antagonism of scavenger receptor CD36 by 5A peptide prevents chronic kidney disease progression in mice independent of blood pressure regulation.

Authors:  Ana Carolina P Souza; Alexander V Bocharov; Irina N Baranova; Tatyana G Vishnyakova; Yuning G Huang; Kenneth J Wilkins; Xuzhen Hu; Jonathan M Street; Alejandro Alvarez-Prats; Adam E Mullick; Amy P Patterson; Alan T Remaley; Thomas L Eggerman; Peter S T Yuen; Robert A Star
Journal:  Kidney Int       Date:  2016-04       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.